Thomson Reuters analysts have disclosed 10 deals – five biopharma licensing and five M&A deals concluded in 2014 – as candidates for the Breakthrough Alliance Awards, with voting now open and the winner to be announced at this year's Allicense meeting in San Francisco.
Blueprint Medicines Corp. will bank $15 million as an up-front payment from Cheshire, Conn.-based Alexion Pharmaceuticals Inc. as a kick-off to their strategic collaboration that will center on an undisclosed activated kinase target, which is the cause of a rare genetic disease.
Thomson Reuters analysts have disclosed 10 deals – five biopharma licensing and five M&A deals concluded in 2014 – as candidates for the Breakthrough Alliance Awards, with voting now open and the winner to be announced at this year's Allicense meeting in San Francisco.
Thomson Reuters analysts have disclosed 10 deals – five biopharma licensing and five M&A deals concluded in 2014 – as candidates for the Breakthrough Alliance Awards, with voting now open and the winner to be announced at this year's Allicense meeting in San Francisco.
In 2011, the National Research Council (NRC) published a report, titled "Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease," which set the ball rolling on changing our current thinking about use of the term "personalized medicine." The report preferred "precision medicine" to convey a more accurate tailoring of medical treatment to the individual characteristics of each patient, not just merely a personalized approach that involved the creation of medicines that are unique to a patient.
Precision medicine has been capturing the headlines big time in the past couple of weeks with major initiatives being created in the U.S. and the UK. Their objective is to marshal resources to be able to accelerate the discovery and delivery of targeted therapies to patients more effectively.
Oxford, UK-based Summit Corp. plc has filed an F-1 with the SEC, seeking to raise $40 million in an initial public offering (IPO). The company said it plans to use the capital raised to help drive its clinical programs focused on Duchenne muscular dystrophy (DMD) and Clostridium difficile infection (CDI).
It was a volatile month for the capital markets at just one trading day left before the curtain closed on the first month of the year. The markets experienced wild swings throughout January. Despite the uncertainties, the industry has got off to a red hot start to the year with the BioWorld Biotech Blue Chip index, a price-weighted index that includes 20 of the top biotech companies by market cap, recording a strong 6.5 percent jump in value compared to the lackluster 1.1 percent drop in the Nasdaq composite Index and a 2.3 percent slide in the Dow Jones Industrial average over the same period.
Public-private partnerships (PPPs) are at the forefront of a changing paradigm in the approach to successfully developing new medicines. Those partnerships or consortia are part of an effort to transform the expensive, time-consuming, high-risk and complicated process that eventually leads to new treatment options.
